Legend Biotech Corp
1 day chart
Legend Biotech Corporation is a global, clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). It has a portfolio of early stage autologous product candidates targeting various cancers, including, gastric cancer, and T cell Lymphoma (TCL), both of which are in investigator-initiated phase I clinical trials. It is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of Non-Hodgkins Lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), and acute lymphoblastic leukemia (ALL). It also has several allogeneic platforms under development targeting BCMA.
Buy US stocks in Australia starting with LEGN. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in LEGN
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.